Iparomlimab tovorilimab bevacizumab mesothelioma trial
Summary
NIH registered a new Phase 2 clinical trial (NCT07514793) on ClinicalTrials.gov evaluating the combination of iparomlimab, tovorilimab, and bevacizumab for the treatment of mesothelioma. The trial is sponsored by Memorial Sloan Kettering Cancer Center and appears to be an open-label study investigating this immunotherapy combination. ClinicalTrials.gov serves as the primary registry for clinical trials conducted under FDA oversight.
What changed
A new clinical trial registration was added to ClinicalTrials.gov for a Phase 2 study evaluating the combination of iparomlimab (anti-LAG-3), tovorilimab (anti-TIGIT), and bevacizumab (anti-VEGF) in patients with mesothelioma. The trial is registered as NCT07514793 and is sponsored by Memorial Sloan Kettering Cancer Center.
Healthcare providers, particularly oncologists and cancer researchers, should note this trial registration as it represents an emerging immunotherapy combination approach for mesothelioma, a cancer with limited treatment options. Pharmaceutical companies involved in immuno-oncology drug development may find this registration relevant for tracking competitive trial activity in the checkpoint inhibitor space targeting LAG-3, TIGIT, and VEGF pathways.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.